PRESS RELEASE : Vivoryon Therapeutics N.V. new ISIN code

 
 DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Corporate Action 
Vivoryon Therapeutics N.V. new ISIN code 
 
2021-01-06 / 07:00 
The issuer is solely responsible for the content of this announcement. 
 
*Vivoryon Therapeutics N.V. new ISIN code* 
 
*HALLE (SAALE) / MUNICH, Germany, 06 January 2021* - in connection with the 
conversion into an N.V., a public company under the laws of the Netherlands 
(_naamloze vennootschap_, "N.V.") which has taken effect on 28 November 
2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announces that 
the shares will be trading under a new ISIN NL00150002Q7 as from 11 January 
2021. The last trading date of the shares under the ISIN DE0007921835 will 
be 08 January 2021. The ISIN code change will be effected automatically. 
Trading in Vivoryon Therapeutics shares will not be affected. The central 
securities depository for the shares under ISIN NL00150002Q7 will be 
Euroclear Nederland (_Nederlands Centraal Instituut voor Giraal 
Effectenverkeer B.V._). 
 
### 
 
*For more information, please contact:* 
*Vivoryon Therapeutics N.V.* 
Dr. Ulrich Dauer, CEO 
Email: [e-mail] 
 
*Trophic Communications* 
Gretchen Schweitzer / Joanne Tudorica 
Tel: [phone] 
Email: [e-mail] 
 
*About Vivoryon Therapeutics N.V.* 
With 20+ years of unmatched understanding in identifying post-translational 
modifying enzymes that play critical roles in disease initiation and 
progression, Vivoryon's scientific expertise has facilitated the creation of 
a discovery and development engine for small molecule therapeutics. This 
platform has demonstrated success by developing a novel therapeutic in type 
2 diabetes. In its current programs Vivoryon Therapeutics is advancing its 
lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire 
portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In 
addition, the company pursues a development program for Meprin protease 
inhibitors with potential therapeutic use in fibrotic diseases, cancer and 
acute kidney injury. 
www.vivoryon.com [1] 
 
*Forward Looking Statements* 
Information set forth in this press release contains forward-looking 
statements, which involve a number of risks and uncertainties. The 
forward-looking statements contained herein represent the judgment of 
Vivoryon Therapeutics N.V. as of the date of this press release. Such 
forward-looking statements are neither promises nor guarantees but are 
subject to a variety of risks and uncertainties, many of which are beyond 
our control, and which could cause actual results to differ materially from 
those contemplated in these forward-looking statements. We expressly 
disclaim any obligation or undertaking to release publicly any updates or 
revisions to any such statements to reflect any change in our expectations 
or any change in events, conditions or circumstances on which any such 
statement is based. 
 
2021-01-06 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Vivoryon Therapeutics N.V. 
             Weinbergweg 22 
             06120 Halle/Saale 
             Germany 
Phone:       [phone] 
Fax:         [phone] 
E-mail:      [e-mail] 
Internet:    www.vivoryon.com 
ISIN:        DE0007921835 
WKN:         792183 
Listed:      Regulated Unofficial Market in Berlin, Frankfurt, Munich, 
             Stuttgart; Amsterdam 
EQS News ID: 1158702 
 
End of News DGAP News Service 
 
1158702 2021-01-06 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=41d29022a53944e2850469d63ade149d&application_id=1158702&site_id=vwd&application_name=news

(END) Dow Jones Newswires

January 06, 2021 01:00 ET (06:00 GMT)